Zacks Research Issues Optimistic Estimate for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities research analysts at Zacks Research lifted their Q2 2026 earnings per share estimates for shares of Theravance Biopharma in a report issued on Monday, January 13th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of ($0.11) per share for the quarter, up from their previous estimate of ($0.12). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $8.44 on Thursday. The company has a market cap of $415.03 million, a price-to-earnings ratio of -8.36 and a beta of 0.21. The firm has a 50-day moving average of $9.48 and a 200-day moving average of $8.89. Theravance Biopharma has a one year low of $7.44 and a one year high of $10.44.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $16.87 million during the quarter, compared to analyst estimates of $16.11 million. During the same quarter last year, the business earned ($0.17) earnings per share.

Institutional Trading of Theravance Biopharma

A number of large investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in shares of Theravance Biopharma in the third quarter valued at approximately $60,000. China Universal Asset Management Co. Ltd. lifted its position in Theravance Biopharma by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 3,696 shares during the last quarter. Ballentine Partners LLC bought a new stake in shares of Theravance Biopharma during the third quarter worth approximately $104,000. Hsbc Holdings PLC acquired a new position in shares of Theravance Biopharma in the second quarter valued at approximately $108,000. Finally, XTX Topco Ltd bought a new position in shares of Theravance Biopharma during the second quarter worth approximately $129,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 322,743 shares in the company, valued at $2,904,687. This trade represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is currently owned by corporate insiders.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.